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Abstract
Background: Activated protein C (PC) is a serine protease that regulates blood coagulation by inactivating
coagulation factors Va and VIIIa. PC deficiency is an autosomally inherited disorder associated with a high risk of
recurrent venous thrombosis. The aim of the study was to explore the mechanisms responsible for severe PC
deficiency in a patient with the protein C A267T mutation by in-vitro expression studies.
Results: Huh7 and CHO-K1 cells were transiently transfected with expression vectors containing wild-type (WT PC)
and mutated PC (A267T PC) cDNAs. PC mRNA levels were assessed by qRT-PCR and the PC protein levels were
measured by ELISA. The mRNA levels of WT PC and A267T PC were similar, while the intracellular protein level of
A267T PC was moderately decreased compared to WT PC. The secretion of A267T PC into the medium was
severely impaired. No differences in molecular weights were observed between WT and A267T PC before and after
treatment with endo-b-N-acetylglucosaminidase. Proteasomal and lysosomal degradations were examined using
lactacystin and bafilomycin, respectively, and revealed that A267T PC was slightly more susceptible for proteasomal
degradation than WT PC. Intracellular co-localization analysis indicated that A267T PC was mainly located in the
endoplasmic reticulum (ER), whereas WT PC was observed in both ER and Golgi.
Conclusions: In contrast to what has been reported for other PC mutants, intracellular degradation of A267T PC
was not the main/dominant mechanism underlying the reduced intracellular and secretion levels of PC. Our results
indicate that the A267T mutation most likely caused misfolding of PC, which might lead to increased retention of
the mutated PC in ER.
Background
Protein C (PC) is a vitamin-K dependent zymogen,
which upon activation to a serine protease, plays an
important role in the regulation of blood coagulation
through the inactivation of factors Va and VIIIa [1]. PC
deficiency is an autosomally inherited disorder asso-
ciated with increased risk of venous thrombotic compli-
cations, such as deep vein thrombosis and pulmonary
embolism [2,3].
Human PC is synthesized as a 461 amino acid single
polypeptide chain that undergoes extensive post-transla-
tional modifications including signal peptide cleavage,
g-carboxylation, b-hydroxylation, and N-linked glycosy-
lation before it is secreted by the liver [4]. PC circulates
in the plasma in several glycoforms and it has been
shown that glycosylation of human PC affects its secre-
tion, processing and antithrombotic activities [5]. A
wide variety of genetic mutations in the PC gene
(PROC) have been shown to be associated with PC
abnormalities http://www.itb.cnr.it/procmd/. Most of
these are missense mutations although a few nonsense
and frameshift mutations, or splice-site abnormalities
have been reported as well [6]. Several in vitro expres-
sion studies have investigated the molecular mechanisms
of mutations in the PROC gene associated with PC defi-
ciency. Results from these studies indicated that
mutated PC variants were secreted inefficiently from
transfected cells compared to wild-type (WT) PC [7-15].
Some of the studies also demonstrated that the intracel-
lular levels of the mutated PC were decreased compared
to WT PC, suggesting increased intracellular
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degradation of the mutated PC to be a dominant path-
way behind the impaired secretion [8,10,11,15].
In eukaryotic cells, intracellular degradation of
mutated proteins is known to be carried out by two
main proteolytic pathways, namely endoplasmic reticu-
lum (ER) associated degradation (ERAD) (through pro-
teasomes) or autophagy (through lysosomes) [16]. Most
secretory proteins first enter the ER where they are sub-
jected to post-translational modifications and folding
prior to their transit to Golgi and subsequent to the cell
surface [17,18]. Only properly modified and folded pro-
teins are supposed to exit the ER. Most misfolded pro-
teins are retained within the ER lumen in complex with
molecular chaperones, then retrogradely transported to
the cytosol and eventually degraded through the protea-
somes [15,19-22]. Misfolded proteins not transported to
the cytosol may aggregate transiently or permanently in
ER [17]. Accumulation of misfolded proteins in ER can
cause ER stress and activation of a protective response
known as unfolded protein response (UPR), which
implicate three different mechanisms to restore homeos-
tasis: attenuation of protein synthesis, optimization of
chaperone-assisted protein folding and activation of pro-
tein degradation [23]. Several studies have revealed that
protein degradation in ERAD can be compromised
under ER stress resulting in insufficient proteasomal
degradation [24,25]. The mechanisms associated with
the intracellular processing of mutant proteins are com-
plex and sorting of proteins for ERAD remains poorly
understood. Criteria such as molecular chaperones, con-
formation and folding factors are most likely involved in
targeting of mutated proteins for degradation [26,27].
Previous studies have shown that mutations in the PC
molecule caused PC deficiency due to impaired trans-
port of PC from ER [7,10,13] and some of the studies
also detected increased degradation by proteasomes
[15,20,28].
The aim of the present work was to characterize the
A267T PC mutation previously reported in a patient with
PC deficiency [29]. Using site-directed mutagenesis to gen-
erate A267T PC cDNA and subsequent transient transfec-
tions, we explored the potential molecular mechanism(s)
by which this mutation may cause a reduction of the PC
level in the plasma of the patient. It should be emphasized
that results obtained with in-vitro studies after overexpres-
sion of proteins, may differ from the in-vivo situation.
However, it is likely that the potential mechanisms
involved will be revealed. We found that the A267T PC
levels in transfected cells and culture medium were
strongly reduced compared to the level of WT PC despite
of no differences in the steady state levels of the A267T
and WT PC mRNA. Similar to other PC mutants, the
A267T PC had impaired intracellular transport, however,
only a small fraction of the A267T PC was degraded by
the proteasomes.
Results
Transient expression of WT and A267T PC
To investigate the effect of the A267T mutation on the
synthesis and secretion of PC, we transiently transfected
CHO-K1 and Huh7 cells with WT PC or A267T PC
cDNA constructs. Assessment of PC levels in the cell
lysates and the corresponding medium revealed that the
total amount of the A267T PC mutant was severely
reduced in CHO-K1 cells (Figure 1A). The intracellular
levels of A267T PC were significantly lower, 57 and 77%
relative to the WT PC levels 24 and 48 h after transfection,
respectively. A dramatic reduction in the amount of
secreted A267T PC was detected, 14 and 16% of the WT
PC secretion levels 24 and 48 h after transfection, respec-
tively. Similar results were obtained in Huh7 cells, which
have endogenous expression of protein C (Figure 1B). The
corresponding results were 66 and 50% of the intracellular
WT PC levels and 29 and 17% of the secreted WT PC
levels. The results strongly indicate that the mutation
affects both the synthesis and the secretion of the protein.
No PC antigen was detected in CHO-K1 cells transfected
with empty vector. All results for PC concentration were
adjusted for total protein (TP) concentration but similar
results for PC expression were also obtained for PC con-
centration not adjusted for TP. We then examined
whether the reduced total amount of A267T PC was due
to differences in the mRNA steady state levels of the two
PC variants. The mRNA expression levels of WT and
A267T PC were determined by quantitative RT-PCR in
transiently transfected cells. No differences in the PC
mRNA levels were detected between A267T PC and WT
PC either in CHO-K1 or in Huh 7 cells (Figure 2A, B).
N-linked glycosylation and Western analysis
Protein C has four potential sites for N-glycosylation. It
has previously been shown for other PC mutants that
their destiny was dependent on N-linked glycosylation
[28]. Thus, a possibility existed that the reduced intra-
cellular levels and secretion of A267T PC could be due
to differences in N-linked glycosylation between the two
protein variants. Lysates from cells transiently trans-
fected with plasmid constructs expressing WT or
A267T PC, were treated with Endo-H enzyme followed
by Western blot analysis (Figure 3A). The molecular
weights of the two bands of WT and A267T PC were
equally reduced compared to lysates from untreated
cells. The molecular weights of secreted WT and A267T
PC were the same for both variants and importantly not
affected by Endo-H (Figure 3B). This indicated that only
fully processed PC molecules were secreted. As seen for
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the untreated samples, the A267T mutation did not
affect the size of PC since no differences in the molecu-
lar weights were observed between the mutant and WT
PC.
Stability and degradation of WT and A267T PC
Since no differences in the steady state levels of mRNA
for the two PC variants were observed, the reduced
intracellular level of A267T PC compared to the WT
level could be explained by alterations in stability of the
mutated PC. To determine the half-lives of the two PC
variants, transient transfected CHO-K1 cells were trea-
ted with the protein synthesis inhibitor cycloheximide
(CHX) for various time-points. The half-lives were
found to be five and six hours (h) for WT and A267T
PC, respectively (data not shown). In fact, this indicated
that the mutant was slightly more stable than the WT
PC. Therefore, we aimed to examine whether the differ-
ences in intracellular protein levels could be due to
changes in degradation. Transiently transfected CHO-
K1 cells were treated with the proteasomal degradation
inhibitor lactacystin or the lysosomal degradation inhibi-
tor bafilomycin (Table 1). Treatment with lactacystin
resulted in a modest, although statistically significant
(p = 0.045) difference between the PC variants. WT and
A267T PC levels were elevated (19.8% and 31.8%,
respectively) compared to the intracellular PC levels in
corresponding untreated cells, suggesting a slight
Figure 1 Reduced level of A267T PC in transiently transfected cells. CHO-K1 (A) and Huh7 (B) cells were transiently transfected with plasmid
constructs expressing WT or A267T PC. The culture medium (’white square’) and cell lysates (’black square’) were harvested 24 and 48 h after the
transfection. The PC levels were measured using an ELISA kit and the PC levels in Huh7 were adjusted to the endogenous PC levels in these
cells as described in Methods. The concentration of PC was adjusted to TP concentration in the corresponding sample. Histograms and the bars
represent the mean and SEM values for CHO-K1 (n = 9) and for Huh7 cells (n = 8). * p < 0.05 (Mann-Whitney test, A267T PC versus WT PC).
Figure 2 No differences in mRNA levels between WT and A267T PC. CHO-K1 (A) and Huh7 cells (B) were transiently transfected with
plasmid constructs expressing WT or A267T PC. Cells were harvested 24 h after transfection and total RNA was isolated. PC mRNA levels were
determined using quantitative RT-PCR with 18 S and GAPDH as endogenous controls for CHO-K1 and Huh7 cells, respectively. The mRNA PC
levels i Huh7 cells were normalized for the endogenous mRNA PC levels. The results are presented as ratio between mRNA levels of WT and
A267T PC with the WT PC level assigned as 1. The results are from three independent transfection experiments performed in triplicates and
presented as mean ± SEM.
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increase in proteasomal degradation of A267T PC com-
pared to WT PC. The bafilomycin treatment resulted
only in a non-significant minor increase of both WT PC
(12.6%) and A267T PC (6.7%) intracellular levels, and
indicated no lysosomal degradation of the PC variants
(Table 1).
Intracellular localization of WT and A267T PC
Since no major differences in stability and degradation
between WT and A267T PC could account for the low
levels of the mutated protein, we speculated whether the
two variants might have different intracellular distribu-
tion. It has previously been reported that abnormal pro-
tein C molecules were retained in the ER [7,10,13]. We
therefore examined the localization of PC in transiently
transfected CHO-K1 cells by immunofluorescence analy-
sis. In order to explore the location of WT and A267T
PC, the cells were doublestained with antibodies against
PC and either the ER marker PDI or the Golgi marker
GM130. Figure 4 demonstrates that both WT and
A267T PC co-localized with PDI and GM130 while the
A267T PC co-localized with GM130 in a much less
extent than did WT PC. These results indicated that
A267T PC was predominantly localized in the ER and
transported to the Golgi with less efficiency compared
to WT PC.
Discussion
The present study provides evidence that the mechan-
ism of PC deficiency caused by the A267T mutation
[29] most likely involves impaired synthesis and also
reduced secretion of the mutant. In contrast to what has
been demonstrated for several other PC mutations caus-
ing PC deficiency [15,20,28], the effect of the present
Figure 3 N-linked glycosylation and Western analysis. Lysates (A) and culture medium (B) from Huh7 and CHO-K1 cells transiently
transfected with plasmid constructs expressing WT or A267T PC were harvested 48 h after transfection and treated ± Endo-H for 18 h at 37°C.
After completion of the reaction, the samples were analyzed by 10% SDS-PAGE under reducing conditions. Following blotting onto a PVDF
membrane and subsequent incubation with antibody against PC, the bands were visualized with ECL. Equal amounts of PC (as measured by
ELISA) in cell lysates and culture medium were analyzed.
Table 1 Effect of protein degradation inhibitors on
intracellular PC levels.
Treatments Intracellular WT PC
(%)
Intracellular A267T PC
(%)
Control 100 100
Lactacystin (10 μM),
n = 8
119.8 ± 3.3* 131.8 ± 4.4*
Bafilomycin (100 nM),
n = 9
112.6 ± 4.9 106.7 ± 7.2
Transient transfected CHO-K1 cells expressing WT or A267T PC were
incubated with medium containing 10 μM lactacystin or 100 nM bafilomycin
for 24 and 8 h, respectively. PC protein levels were measured in cell lysates
and results are calculated as percentage of controls (samples not treated with
protein degradation inhibitors). Data are presented as mean ± SEM. *p < 0.05
(Wilcoxon test).
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mutation on proteasomal degradation was minimal.
However, like other PC mutations [7,10,13], the A267T
variant was retained in the ER. Transient expression
analysis demonstrated that the A267T PC protein levels
secreted into the culture medium were seven and five
fold less compared to WT PC in CHO-K1 and Huh7
cells, respectively. The intracellular levels of the A267T
PC were also strongly reduced. No major differences in
mRNA levels, half-lives or degradation were detected for
the two PC variants. Immunofluorescence staining
revealed that the mutant was observed mainly in ER
while WT PC was detected both in ER and in Golgi
indicating a rapidly processing and secretion of WT PC,
while the majority of mutated PC most likely was
retained in the cells in an attempt to be folded correctly.
PC deficiency is an inherited disorder associated with
a high risk of recurrent venous thrombosis [2,3]. In vitro
studies of various mutations in the PROC gene have
Figure 4 Intracellular localization of WT and A267T PC. CHO-K1 cells were grown on coverslips and transiently transfected with plasmid
constructs expressing WT or A267T PC. Forty-eight h after transfection the cells were fixed and stained with anti-PC and anti-PDI (ER marker) or
anti-GM130 (Golgi marker). PC appears red, PDI and GM130 appears green and overlaid images is yellow and corresponds to areas of co-
localization of PC with ER and Golgi. Scale bar, 10 μm.
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provided insight into how these mutations can cause PC
deficiency [7-15,20,28]. Most of these studies revealed
that the PC deficiency was due to impaired secretion
caused by intracellular degradation of the mutated pro-
teins [8,10,11,15,20,28]. Enhanced proteolytic degrada-
tion of mutated proteins is a common molecular
pathological mechanism in many diseases [30]. Degrada-
tion is often associated with impaired intracellular trans-
port of proteins in the producing cells [31]. Intracellular
protein transport through the secretory pathway in
eukaryotic cells depends on a proper folding of proteins
in ER [17,18]. Several transfection studies have described
impaired transport of proteins from ER to Golgi due to
prolonged binding of the mutated proteins with chaper-
ones which facilitate a folding process in ER [7,32].
Mutated/misfolded proteins are frequently subjected to
subsequent degradation by quality control mechanisms
involving ERAD [17]. Not all mutated proteins will be
recognized as misfolded by the ER quality control sys-
tem. Some of them can remain in ER for an extended
time period without being sent for disposal in ERAD
[24,33-35]. It can be speculated whether the effect a
mutation has on 3 D structure of a protein can deter-
mine which mechanism that will be chosen in each par-
ticular case. It is likely that mutations, which are able to
cause severe conformational changes, trigger ERAD to
become hyperactive resulting in nearly complete degra-
dation of the mutated proteins whereas a mutation with
minor effects on the protein structure can result in sev-
eral rounds of the folding process and thereby increased
ER retention and attenuated degradation. The latest
database on 3D-structure of PC http://www.itb.cnr.it/
procmd/, obtained by computational approaches, inter-
preted the A267T mutation as not being disruptive for
the structure and function of PC. In addition, alignment
of the PC amino acid sequence and other evolutionary
related human vitamin-K-dependent factors revealed
that the A267 is not strictly conserved. All these facts
may indicate that the investigated mutation leads to
only minor effects on the PC molecule and inefficient
ERAD degradation.
The fact that the intracellular level of A267T PC was
reduced and the mutated PC was not degraded faster
compared to WT PC could indicate that mRNA transla-
tion might be affected as indicated by other reports
[32,36]. The most immediate response to ER stress,
which can occur as a result of misfolded protein accu-
mulation in ER, is transient attenuation of mRNA trans-
lation which prevents influx of newly synthesized
polypeptides in ER [16,23]. Although no evidence of ER
stress is presently available, one might speculate that
reduced mRNA translation of mutated PC as a result of
UPR could explain the fact that the intracellular levels
of A267T PC was reduced compared to the WT PC
levels. In-vitro translation experiments might have
revealed if this was the case. Since the effect of inhibi-
tion of proteasomal degradation in this study was found
to be insufficient to explain the reduced intracellular
and secreted levels of A267T PC, the involvement of
additional degradation pathways can not be ruled out. A
small number of mutated secretory proteins have been
reported to be degraded both by proteasomes and other
cytosolic proteases (often serine/cysteine) simultaneously
[37-39].
In some of the previous studies where the proteasomal
degradation was found to be the dominant mechanism
of PC deficiency [15,20,28], it was shown that this
degradation was independent of ubiquitinylation of
mutated PC. Ubiquitinylation is essential in several cel-
lular processes including targeting proteins for proteaso-
mal degradation and is catalyzed by the sequential
action of various enzymes [40]. In our study, we found
that inhibition of ubiquitinylation by pyrazone (PYR-41)
had no effect on the PC levels of either WT or A267T
PC (data not shown) and indicated that proteasomal
degradation of the investigated PC variants was indepen-
dent of ubiquitin.
Intracellular protein transport through the secretory
pathway in eukaryotic cells consists of translocations
from ER to Golgi and from Golgi to secretory vesicles
[41]. Like other secretory glycoproteins, PC undergoes
post-translational processing such as glycosylation, g-
carboxylation and b-hydroxylation. N-linked glycosyla-
tion of PC takes place before transport to the Golgi
apparatus and possibly as a co-translational event in ER.
On their way through the Golgi, the carbohydrate side
chains of PC undergo further modifications which lead
to resistance against Endo-H treatment of the protein in
Golgi [42]. The Endo-H digestion analysis in the present
study revealed that both WT and A267T PC proteins in
the cell lysates were sensitive to the Endo-H treatment,
indicating that the PC was localized predominantly to
the ER. However, the immunofluorescence analysis in
this study demonstrated that a fraction of WT PC was
located in Golgi, and thus, we expected some of the cel-
lular WT PC to be resistant to Endo-H. This was how-
ever, not the case. In agreement with other studies
[10,15] we therefore assume that most WT PC resided
in the ER and was secreted quickly subsequent to post-
translational modifications.
Conclusions
In the present study we have transiently transfected cells
with cDNAs encoding WT and A267T PC and found
that the mutation led to reduced intracellular levels and
impaired secretion of the mutant protein relative to the
WT PC. The level of secreted PC mutant was in agree-
ment with the observed plasma PC protein level in our
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patient who had 12% of the normal level [29]. The dif-
ferences in protein levels of the two PC variants were
not due to reduced transcription of the mutated gene.
The A267T PC was mainly localized in the ER and pre-
sumably transported to Golgi with less efficiency com-
pared to WT PC. This could account for the reduced
secretion of the mutant. Since the reduced intracellular
levels and secretion of A267T PC could not be
explained by differences in proteasomal or lysosomal
degradation, other mechanisms, such as intracellular
degradation mediated by other numerous cytosolic pro-
teases and/or reduced mRNA translation, cannot be
ruled out.
Methods
Cell cultures
Chinese hamster ovary (CHO-K1, CCL-61) and human
hepatoma (Huh7, RCB 1366) cells were obtained from
ATCC (American Type Culture Collection, Rockville,
MD). Cells were cultivated in Dulbecco’s Modified
Eagles Medium (DMEM) (Cambrex BioScience, Ver-
viers, Belgium) supplemented with 100 IU/ml penicillin,
100 μg/ml streptomycin, and 10% foetal calf serum
(FCS) (Biowhittaker (TM), Luna, Belgium). Cells were
incubated at 37°C in a humidified atmosphere with 95%
air and 5% CO2.
Site-directed mutagenesis and construction of the
expression vectors
Total RNA from Huh7 cells was isolated using the ABI
PRISM 6100 system (Applied Biosystems, Foster City,
CA) following the manufacturer’s procedure. Full-length
PC cDNA was amplified by PCR with the following pri-
mers (forward primer, 5’-GAC GGC GAA CTT GCA
GTA T-3’ and reverse primer, 5’-ATC CCC CTC AAC
ACA CAC AG - 3’) (Eurogentec, Seraing, Belgium). The
obtained cDNA was cloned into the pcDNA3.1/V5-His-
TOPO vector (pPROC-WT) (Invitrogen, Carlsbad, CA).
cDNA for the A267T PC variant was created using the
Quick®Change Site-Directed Mutagenesis Kit (Strata-
gene, Amsterdam, Netherlands) according to the manu-
facturer’s instructions. The primers were as follows
(forward primer, 5’-CTG CAC CTG GCC CAG CCC
ACC ACC CTC TCG CAG ACC ATA GTG CCC-3’
and reverse 5’-GGG CAC TAT GGT CTG CGA GAG
GGT GGT GGG CTG GGC CAG GTG CAG-3’ (Euro-
gentec). The entire sequence of both PC cDNAs was
confirmed using gene specific (Eurogentec) and vector
(Invitrogen) primers.
Transient transfections
For transient transfections, CHO-K1 and Huh7 cells
were grown to 70-80% confluence in six-wells plates
one day prior to the transfection. The transfections were
performed with FuGENE-6® Transfection Reagent
(Roche, Mannheim, Germany) at a 1:6 ratio (DNA:
FuGENE-6® Reagent) following the manufacturer’s
instructions. 1 μg plasmid DNA was used per well. For
each transfection reaction, empty vector was used as a
negative control. The transfection efficiency was evalu-
ated by co-transfection with pRcCMV/CAT plasmid
(Invitrogen). The activity of chloramphenicol acetyl-
transferase (CAT) was measured using CAT-ELISA Kit
(Roche) and no statistical significant differences (Mann-
Whitney test) of CAT activities were observed in lysates
from cells co-transfected with either pPROC-wt or
pPROC-A267T (CHO-K1, p = 0.507 and Huh7, p =
0.186). The median and range of CAT activities (arbi-
trary units) in lysates were 15.1 (10.2-21.9) for pPROC-
WT and 13.7 (11.1-17.5) for pPROC-A267T in CHO-K1
cells and 6.5 (3.9-8.6) for pPROC-WT and 5.9 (3.6-8.2)
for pPROC-A267T in Huh7 cells.
PC expression measurements by ELISA
24 and 48 h after transfection, the culture medium was
collected and the cells were washed three times with
pre-chilled phosphate-buffered saline (PBS) before
extraction in 800 μl of ice-cold RIPA lysis buffer con-
taining a protease inhibitor cocktail (Sigma-Aldrich, St.
Louis, MO). PC antigen concentrations in cell lysates
and culture medium were measured using the Elisara
Protein C Kit (Aniara, Mason, OH). The total protein
concentration in cell lysates was measured by the Lowry
Bio-Rad DC Protein Assay (Bio-Rad, Hercules, CA). PC
antigen levels in cell lysates or culture medium were
normalized against the total protein concentrations of
the corresponding lysate samples. The results for Huh7
cells were normalized by subtracting the endogenous PC
levels.
Quantitative RT-PCR (qRT-PCR)
24 h after transfection the cells were washed with pre-
chilled PBS and lysed in 800 μl Nucleic Acid Purifica-
tion Lysis Solution (Applied Biosystems). Total RNA
was isolated using the ABI PRISM 6100 System (Applied
Biosystems) according to the manufacturer’s procedure
and quantified with a NanoDrop ®ND-1000 Spectrophot-
ometer (NanoDrop Technologies, Wilmington, DE).
600-1200 ng of total RNA was reversely transcribed
using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems) with random primers accord-
ing to the manufacturer’s procedure. PC mRNA levels
were determined by the 7900 HT Fast Real-Time PCR
System (Applied Biosystems) using a TaqMan®Gene
Expression Assay for PC (Applied Biosystems) and Taq-
Man®Universal Master mix (Applied Biosystems) accord-
ing to the manufacturer’s instructions. As endogenous
controls for normalization of the amount RNA in the
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reaction and for RT efficiency, assays for the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) and the
transferrin receptor (TFRC) cDNAs were used for Huh7
cells, and the TATA binding protein (TBP) and small
subunit rRNA (18S) cDNAs for the CHO-K1 cells. The
PC mRNA levels in Huh7 cells were normalized for the
endogenous PC mRNA levels. All assays were from
Applied Biosystems. Negative controls without cDNA
were always included.
N-linked glycosylation and Western analysis
Cell lysates for the deglycosylation reactions were pre-
pared from cells transiently transfected to express WT-
PC or A267T PC. The cells were harvested 48 h after
transfection and washed with pre-chilled PBS followed
by the addition of 800 μl of ice-cold RIPA lysis buffer
containing a protease inhibitor cocktail (Sigma-Aldrich).
The cell lysates and the corresponding media were then
incubated with an endo-b-N-acetylglycosaminidase
(Endo-H) enzyme (Roche) for 18 h at 37°C according to
the manufacturer’s instructions. Following deglycosyla-
tion, the samples were resolved on a 10% SDS-PAGE
gel under reduced conditions and electroblotted onto a
PVDF membrane (Millipore, Bedford, MA). After block-
ing in 5% (w/v) non-fat milk in TBS-T buffer (Bio-Rad)
the membranes were incubated with rabbit anti-human
antibodies against PC (1 μg/ml, Aniara) overnight at 4°C
followed by an incubation with a horseradish peroxi-
dase-conjugated goat anti-rabbit IgG antibody (0.1 μg/
ml, Santa Cruz) for 1 h at room temperature. Proteins
were visualized with the ECL Western blot detection kit
(Pierce, Rockford, IL) on High Performance chemilumi-
niscence film (GE Healthcare, Buckinghamshire, UK).
Degradation studies
To determine the intracellular half-lives of WT and
A267T PC, CHO-K1 cells were transiently transfected
with pPROC-WT and pPROC-A267T and grown for
24 h. The cells were then treated with CHX (50 μg/ml)
(Sigma-Aldrich) in serum-free medium for various time-
points. Intracellular PC antigen and total protein levels
were determined as described above. To examine the
potential degradation through the proteasomal and lyso-
somal pathways, transiently transfected cells were trea-
ted ± 10 μM lactacystin (Sigma-Aldrich) or 100 nM
bafilomycin (Sigma-Aldrich) for 24 and 8 h, respectively.
The agents were added 24 h post transfection. PC anti-
gen and total protein levels in cell lysates were deter-
mined as described above.
Confocal microscopy
CHO-K1 cells (1.1 × 105 cells/well) were grown on cov-
erslips in a six-well plate and transfected with 1 μg of
plasmid using the FuGENE-6 Transfection Reagent
(Roche). Forty-eight h after transfection, the cells were
fixed with 10% formalin solution (Sigma-Aldrich), fol-
lowed by permeabilization in 0.1% Triton X-100 (Sigma-
Aldrich) in PBS and blocking in 5% foetal bovine serum
(FBS) (Biowhittaker (TM), Luna, Belgium). Immunos-
taining was performed with appropriate primary antibo-
dies: rabbit polyclonal anti-PC (Aniara), mouse
monoclonal anti-PDI (Stressgen, Ann Arbor, MI) or
mouse monoclonal anti-GM130 (BD Biosciences, San
Jose, CA) diluted in PBS with 5% FBS. Cy-2 and Cy-3-
conjugated secondary antibodies were from Jackson
Immunoresearch (West Grove, PA). The cells were
mounted in Mowiol 4-88 (Merck Chemicals Ltd, Not-
tingham, UK) and analyzed using the laser scanning
confocal microscope LSM 510 Meta (Carl Zeiss, Jena,
Germany). Images were prepared with the ImageJ soft-
ware (National Institute of Health, USA).
Statistical analysis
All results were tested for the statistical significance
with the non-parametric two-tailed Mann-Whitney and
Wilcoxon tests. p-values <0.05 were considered statisti-
cally significant. GraphPad Prism version 5 (GraphPad
Software, San Diego CA) was used for statistical
analysis.
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